

7 April 2015

## Proposal for supply of diltiazem hydrochloride (Apo-Diltiazem CD)

PHARMAC is seeking feedback on a provisional agreement with Apotex NZ Limited, for diltiazem hydrochloride (Apo-Diltiazem CD) long-acting capsules 120mg, 180mg, and 240 mg from 1 July 2015.

In summary, this proposal would result in:

- long-acting diltiazem hydrochloride remaining listed as the current price and subsidy.
- subsidy and delisting protection until 30 June 2018

### Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Monday, 21 April 2015** to:

Trish Mahoney  
Contract Manager  
PHARMAC  
PO Box 10 254  
Wellington 6143

Email: [trish.mahoney@pharmac.govt.nz](mailto:trish.mahoney@pharmac.govt.nz)  
Fax: 04 916 7542

All feedback received before the closing date will be considered by PHARMAC's Board (or its delegate) prior to making a decision on this proposal.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.

### Details of the proposal

- From 1 July 2015 Apo-Diltiazem CD 120mg, 180mg, and 240mg capsules would remain listed in Section B and Part II of Section H of the Pharmaceutical Schedule at the following subsidy and price (ex-manufacturer and excluding GST):

<b>Chemical</b>	<b>Presentation</b>	<b>Brand</b>	<b>Pack size</b>	<b>Price and subsidy (current and proposed)</b>
Diltiazem hydrochloride	120mg	Apo-Diltiazem CD	500	\$31.83
Diltiazem hydrochloride	180mg	Apo-Diltiazem CD	500	\$47.67
Diltiazem hydrochloride	240mg	Apo-Diltiazem CD	500	\$63.58

- Apo-Diltiazem would have subsidy and delisting protection until 30 June 2018.